tavo412
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2023 (NCT05548634)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
KDR inhibitor
FLT1 inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06761651 | Phase 1 | Dec 20, 2023 | Henan Medical University, Tavotek Biotherapeutics |
| NCT05548634 | Phase 1 | Jan 1, 2023 | Mount Sinai Hospital, Canada, Tavotek Biotherapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tavotek Biotherapeutics | For profit | 2 | 2 | 1 | 2023 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Mount Sinai Hospital, Canada | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1